FIGURE 131.1 Diagram of the collateral pathways for the mesenteric vessels. The celiac axis and superior mesenteric arteries communicate through the superior and inferior pancreaticoduodenal arteries, respectively. The superior and inferior mesenteric arteries communicate through the meandering artery and the marginal artery of Drummond with the meandering artery serving as the dominant collateral. The inferior mesenteric artery communicates with the internal iliac artery through the hemorrhoidal vessels. (From Zelenock GB. Visceral occlusive disease. In: Greenfield LJ, ed. Surgery: Scientific Principles and Practice. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:1691, with permission.)
Mesenteric duplex is an excellent screening tool for visceral artery stenosis with reported sensitivity and specificity rates of approximately 80% (14). However, it is technically challenging, operator dependent, and not available in all centers. A variety of criteria have been proposed to grade the severity of stenoses based upon the systolic/diastolic velocities or frequency shifts with a peak systolic velocity above 275 cm/sec and 200 cm/sec being reliable predictors of greater than 70% stenosis in the superior mesenteric artery and celiac axis, respectively (14,15). A variety of provocative tests have been proposed to unmask clinically significant visceral artery stenoses although their utility is unclear and they have not achieved widespread use (16,17).
Multi-detector helical CT arteriography with 1-mm collimation and three-dimensional reconstructions has largely replaced catheter-based contrast arteriography as the diagnostic study of choice for patients with CMI (Fig. 131.2) and is usually sufficient to plan surgical revascularization (18–20). CT arteriography is safe, noninvasive, and almost universally available. It is very good for identifying occlusive disease in the superior mesenteric artery and celiac axis. Furthermore, it is useful for identifying the presence of collateral vessels between the visceral vessels (i.e., celiac axis, superior mesenteric, inferior mesenteric) and/or the internal iliac arteries that suggest significant stenoses. Additionally, it is very good for evaluating other intra-abdominal processes.
Catheter-based contrast arteriography is very useful for evaluating the visceral circulation and has traditionally been used as the definitive diagnostic test for CMI (Fig. 131.3A). The major advantage of catheter-based arteriography over CT arteriography is that therapeutic interventions can be performed at the time of the diagnostic procedure. Furthermore, intra-arterial pressure measurements can be obtained across a stenosis to determine their hemodynamic significance. However, it is an invasive procedure with a small, but finite complication rate. A lateral arteriogram is mandatory as part of the examination to accurately assess the origins of the celiac axis and superior mesenteric artery due to their anterior/posterior orientation. The significant findings on arteriogram include ostial stenoses of the celiac axis and superior mesenteric artery, the presence of visceral collaterals, and the presence of central aortic atherosclerotic disease. A small percentage of patients with CMI may have visceral artery aneurysms, presumably from increased flow through the collateral vessels.
FIGURE 131.2 CT arteriograms from a patient with chronic mesenteric ischemia and an occluded celiac axis and superior mesenteric artery. A: The origin of the superior mesenteric artery is shown with the arrow. There is no contrast within the lumen of the vessel at this cross section. B: The superior mesenteric artery is shown with the arrow in this cross section that is 10 mm caudal to the first image. The artery is patent at this level as reflected by the contrast within the lumen.
MR arteriography has been used as a diagnostic study for patients with CMI and offers many of the advantages of CT arteriography (21,22). However, it is not as universally available as CT arteriography. Furthermore, it is not practical and may be contraindicated for many patients including those in the intensive care unit. Finally, MR arteriography tends to overestimate the degree of stenosis in the visceral vessels.
FIGURE 131.3 Lateral catheter-based aortograms of a patient with chronic mesenteric ischemia. A: There is a moderate stenosis in the proximal superior mesenteric artery as shown with the arrow. B: No residual stenosis is seen in the superior mesenteric artery after placement of an intraluminal stent.
Treatment Strategies
All patients with CMI require treatment. The natural history of the untreated disease process is death either from inanition or bowel infarction. The theoretical treatment options include medical management with total parenteral nutrition or revascularization by either endovascular or open surgical techniques. The role of long-term parenteral nutrition is very limited given its complexity, expense, and complications, particularly those associated with the infusion catheters. Additionally, patients with CMI may not be able to metabolize the parenteral nutrition. Endovascular treatment (angioplasty +/– stenting) has been adopted by most centers as the initial revascularization option with the open approach reserved for patients with unfavorable anatomy, occlusive disease beyond the vessel origin, and those patients that have failed endovascular treatment (23–36). Endovascular treatment has consistently been shown to have a lower mortality rate, a lower complication rate, and shorter hospital length of stay when compared to open, surgical revascularization. However, the patency rates for the endovascular approach are also lower. Notably, this has not been associated with a decrease in survival and the vessel thrombosis and/or recurrent stenosis has not necessarily resulted in AMI. The recent development of lower profile (i.e., smaller diameter) angioplasty balloon/stent systems has further extended the applications of the endovascular approach (27) and reasonable, short-term results have been reported for patients with occluded (vs. stenotic) vessels (25).
Endovascular Revascularization
The preoperative evaluation prior to endovascular treatment is essentially the same for all catheter-based contrast arteriography. Patients with a contrast allergy should be treated with an appropriate steroid preparation. Patients with elevated serum creatinine levels (serum creatinine 1.5 to 2.0 mg/dL) should receive intravenous hydration and acetylcysteine although admittedly their benefits are somewhat unsubstantiated.
Percutaneous access can be obtained through either the femoral or brachial arteries although the latter is favored for therapeutic procedures given the vectors forces associated with the catheters/sheaths. A flush aortogram is performed in both the anteroposterior and lateral projections. Since most lesions in the superior mesenteric artery and celiac axis are located in the proximal 2 cm of the vessel, selective catheterization is not usually necessary unless a distal lesion is suspected or the extent of the lesion cannot be determined. A greater than 50% diameter reduction of the superior mesenteric artery is usually considered clinically significant regardless of whether or not the celiac axis is involved. In contrast, the diagnosis of CMI should be questioned in the presence of an isolated celiac axis stenosis. Symptomatic stenoses can be treated at the time of the diagnostic arteriogram (Fig. 131.3B). The orificial stenoses in the mesenteric vessels are usually refractory to angioplasty alone and primary stenting is recommended. Balloon angioplasty with selective stenting is reserved for mid-segment lesions. Balloon-expandable stents (vs. self-expanding stents) are preferred for the orificial stenoses due to their superior radial forces and controlled deployment mechanism. Several authors have reported improved patency and reintervention rates with covered stents (compared to bare metal stents) for orificial stenoses with the improved results likely due to the physical barrier of the fabric that inhibits the intimal hyperplastic ingrowth (37–39).
The postoperative care after mesenteric angioplasty/stenting is comparable to that for other peripheral endovascular procedures. Patients are admitted to the general care hospital ward for overnight observation and started on clopidogrel. Most patients notice a marked improvement of their postprandial symptoms shortly after the procedure. A fasting mesenteric duplex ultrasound scan is obtained on the morning after the procedure to serve as a baseline. Elevated velocities are occasionally noted in the duplex scan despite a technically satisfactory arteriographic result and complete resolution of the preoperative symptoms. The explanation for these abnormal duplex findings is unclear although we have elected to follow the patient’s clinical course in this setting and only repeat the arteriogram and/or intervention if there is a recurrence of their symptoms or a significant progression in their abnormal duplex findings. A repeat duplex examination is performed at 1 month and aspirin (325 mg/day) is substituted for the clopidogrel at that time. The subsequent follow-up with serial duplex examination is comparable to that outlined for open revascularization.
Open, Surgical Revascularization
The preoperative workup for patients undergoing open mesenteric revascularization is comparable to that for other major vascular surgical procedures and includes optimization of all organ systems. Multiple algorithms have been developed to reduce the cardiac risk for vascular surgical patients undergoing noncardiac procedures (40) although their utility is unclear given the results of several recent publications (41,42). Regardless of the specific preoperative cardiac evaluation, all patients should likely be an antiplatelet agent and a cholesterol lowering agent (preferably a statin—HMG Co-A reductase inhibitor) (43). A CT or catheter-based contrast arteriogram is mandatory to both confirm the diagnosis and plan the operative procedure. There is no clear cut role for extended preoperative parenteral alimentation to replete the nutritional stores and, indeed, it may be detrimental.
A variety of open, surgical procedures have been reported although the antegrade aortoceliac/superior mesenteric artery bypass (Fig. 131.4) and the retrograde aortosuperior mesenteric artery bypass (Fig. 131.5) are the most common. Unfortunately, the relative infrequency of the problem has prevented the requisite randomized, controlled trials. The advantages of the antegrade aortoceliac/superior mesenteric bypass are that both visceral vessels are revascularized and that the supraceliac aorta (the origin of the bypass) is usually free of atherosclerotic occlusive disease. The major disadvantage is the complexity of the procedure. In contrast, retrograde aortosuperior mesenteric artery bypass is relatively straightforward although only a single vessel is revascularized and the graft is prone to kinking given its obligatory retrograde course that traverses both caudal to cephalad and posterior to anterior. The optimal choice for a specific patient is dictated by their anatomy (i.e., distribution of their occlusive disease) and is contingent upon their comorbidities with the retrograde bypass generally reserved for patients that won’t tolerate the more complex antegrade procedure.
The immediate postoperative care for patients undergoing revascularization for CMI is frequently complicated by the development of multiple organ dysfunction and is distinctly different from that associated with most other abdominal vascular surgical procedures such as aortobifemoral bypass for aortoiliac occlusive disease. This propensity to develop multiple organ dysfunction likely accounts for the prolonged intensive care and total hospital length of stays and is one of the leading causes of death in the postoperative period (44). The responsible mechanism for this multiple organ dysfunction is likely the visceral ischemia and reperfusion phenomenon inherent to the revascularization. This process has been reported to induce a complex response involving several interrelated inflammatory mediators that have the potential to cause both local and distant organ injury (45). In a detailed study, Harward et al. (44) characterized the individual organ system dysfunction after revascularization for both AMI and CMI. They reported that the serum hepatic transaminases (i.e., SGOT, SGPT) increased 90- to 100-fold immediately postoperatively and did not normalize for 7 to 10 days, the platelet counts fell below 40,000 units within 12 to 24 hours and remained abnormal for the first 3 to 6 days, and the prothrombin (PT) and partial thromboplastin (PTT) times became elevated and stayed elevated also for 3 to 6 days. Perhaps most notably, they reported that the overwhelming majority of patients developed a significant pulmonary injury characterized by an elevated mean shunt fraction and a radiographic picture of the acute respiratory distress syndrome that manifested between 1 and 3 days and persisted for 5 to 8 days. Jimenez et al. (9) documented a 64% incidence of multiple organ dysfunction and a 53% incidence of prolonged mechanical ventilation after antegrade revascularization for CMI and further corroborated the findings by Harward et al. (44).
FIGURE 131.4 The completed antegrade bypass from the supraceliac aorta to both the celiac axis and the superior mesenteric artery. (From Huber TS, Lee WA. Revascularization for chronic mesenteric ischemia. In: Zelenock GB, et al., eds. Mastery of Vascular and Endovascular Surgery. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:301, with permission.)
FIGURE 131.5 The completed retrograde bypass from the terminal aorta/proximal right common iliac artery to the superior mesenteric artery bypass. (From Huber TS, Lee WA. Revascularization for chronic mesenteric ischemia. In: Zelenock GB, et al., eds. Mastery of Vascular and Endovascular Surgery. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:301, with permission.)
The optimal management strategy for patients in the early postoperative period after mesenteric revascularization is to support the individual organ systems until the dysfunction resolves. Admittedly, not all patients develop organ dysfunction, but the incidence is quite high and somewhat unpredictable. The optimal ventilator management remains unresolved. Early extubation when feasible, should not be postponed. The thrombocytopenia and coagulopathy are usually managed expectantly with platelet and/or plasma transfusions reserved for severely depressed platelet counts and/or any clinical evidence of bleeding. Notably, the report by Harward et al. (44) suggested that the inherent coagulopathy after mesenteric revascularization was not responsive to vitamin K. Patients should be maintained on total parenteral nutrition throughout the postoperative period until their bowel function returns. This is particularly important given the fact that the majority of patients are severely compromised from a nutritional standpoint. Unfortunately, patients may have a prolonged ileus after revascularization and parenteral nutrition is required for some time. The bypass should be interrogated prior to discharge to confirm the technical adequacy of the reconstruction. Essentially the same imaging studies used to make the diagnosis are options. Our preference is mesenteric duplex although examination in the early postoperative period is frequently compromised by the persistent ileus and the presence of bowel gas. Patients with acute changes in their clinical status should also undergo visceral imaging to confirm that their bypass is patent. It can be difficult to differentiate multiple organ dysfunction that is a sequelae of the ischemia and reperfusion injury from AMI secondary to graft thrombosis. Serum lactate levels may be helpful in this setting.
All patients who undergo revascularization for CMI require long-term follow-up. Patients are usually seen frequently in the early postoperative period until all their active issues resolve and then every 6 months thereafter with a mesenteric duplex to confirm graft patency and to identify any graft or anastomotic-related problems. Objective assessment of graft patency is critical and significantly better than the return of symptoms that has been used as a surrogate marker (46). All abnormalities on duplex imaging merit further investigation with additional imaging and/or intervention.
Diarrhea is a common complaint after revascularization for CMI and can persist for several months. It is more common in patients with preoperative diarrhea and can be so severe that it necessitates total parenteral nutrition. Notably, Jimenez et al. (9) reported that 33% of the patients in their series experienced significant postoperative diarrhea and that it persisted greater than 6 months in 24%. Furthermore, Kihara et al. (47) reported that patients had almost 2 stools/day (1.9 ± 0.4) after revascularization for CMI. The etiology of the diarrhea is unclear but may be related to intestinal atrophy, bacterial overgrowth, or disruption of the mesenteric neuroplexus.
Outcome
The outcome after mesenteric revascularization for CMI is quite good. The perioperative mortality rate after open, surgical revascularization is <5% in high-volume centers and <15% in series reporting the nationwide experience (8–10,12,46–51). The mortality endovascular treatment is consistently <5% (11,23–26,28,29,52–61). The corresponding complication rates are approximately 30% and 15% for the open and endovascular treatments, respectively. The initial technical success rate for the endovascular treatment is approximately 90%. The objectively documented 5-year patency rates after open revascularization are approximately 75%; patency rates after endovascular treatment are not as well described, but likely fall short of those reported for the open treatment. The 5-year survival after either treatment is approximately 75% and most patient return to their pre-symptoms weight.
ACUTE MESENTERIC ISCHEMIA
AMI is the endpoint for several distinct disease processes. Mesenteric emboli and in situ thrombosis are the most common among these and account for approximately 50% and 25% of the cases, respectively (62,63). NOMI (20%), mesenteric venous thrombosis (5%), and aortic dissections account for the balance (62,63). The underlying pathophysiology of AMI is that the impaired intestinal perfusion leads to mucosal compromise. This results in the release of the intracellular contents and the influx of substances (including bacteria) from the lumen of the bowel. This can lead to the activation of the systemic inflammatory response resulting in both local and distant organ dysfunction (e.g., lung injury). If the impaired perfusion persists, bowel infarction with perforation and peritonitis ensues. The immediate clinical concerns for patients with AMI are to reverse the underlying clinical condition and prevent bowel infarction. The clinical presentation, diagnostic approach, and treatment for the various causes of AMI are similar, but there are distinct differences that mandate individual consideration. AMI from an embolus will be discussed in depth given the fact that it is the most common etiology and the respective differences will be highlighted for the other causes. Fortunately, the underlying etiology can usually be determined from the history and clinical setting. Not surprisingly, the morbidity and mortality associated with AMI are significant. The optimal therapy requires prompt diagnosis and definitive treatment although this is often difficult given the susceptible patient population and common clinical scenarios. Indeed, AMI may be either the cause or the effect of the patient’s critical illness.
Embolus
Pathophysiology
The emboli responsible for AMI usually originate from the heart and lodge in the superior mesenteric artery. The intracardiac thrombus is related to atrial fibrillation, an acute myocardial infarction or a ventricular aneurysm. Patients frequently have prior embolic events from the same source although they are not necessarily limited to the superior mesenteric artery (e.g., common femoral artery bifurcation presenting with acute lower extremity ischemia). Notably, the material that comprises these macroemboli is actually quite large as might be predicted from the size of the arteries involved. This is in contradistinction to the micron-sized atheroembolic particles that commonly cause “blue toes” after invasive arteriographic procedures (i.e., artery–artery emboli). The extent of bowel ischemia and/or infarction after an embolus to the superior mesenteric artery is contingent upon the extent of the collateral circulation, the pattern of the arterial occlusion and the duration of the ischemia. In this setting, the bowel progresses from ischemia to infarction in a time-dependent fashion although it may remain viable for 6 to 12 hours. Acute embolic occlusion of the superior mesenteric usually results in ischemia/infarction of the bowel from the mid-jejunum to the transverse colon since the embolic material frequently lodges at the distal superior mesenteric artery beyond the origin of the middle colic. The duodenum and descending colon are usually spared because they are supplied by branches of the celiac axis and inferior mesenteric artery, respectively.
Clinical Presentation and Diagnosis
The diagnosis of AMI from an embolus (or other causes of AMI) may be difficult. The differential list of diagnoses includes all the more common causes of acute abdominal pain. The diagnosis is confounded by the fact that the patients are often critically ill, and, thus, their history/physical examination may not be reliable. Diagnosis requires a high index of suspicion and an aggressive approach since delays in diagnosis adversely affect outcome. This requires an appreciation of the types of patients and clinical scenarios in which AMI occurs including postmyocardial infarction, end-stage renal disease, (64) and postcoronary artery bypass grafting (65–67).
Patients with AMI from an embolus usually present with diffuse abdominal pain. The classic description of the pain secondary to AMI is “pain out of proportion” to the physical findings although this scenario is not always present. Unfortunately, the pain is neither specific nor localized to a particular abdominal quadrant. Peritoneal signs can be present, but they usually occur late in the process and suggest bowel perforation. Patients often experience nausea/vomiting and/or diarrhea, but again these are fairly nonspecific complaints. Notably, AMI is a potent cathartic. Similar to the physical examination, the routine chemistry and hematologic laboratory studies are usually nonspecific and insensitive. Patients frequently have mild abnormalities of their laboratory values including an elevated white blood count, a decreased platelet count, an elevated hematocrit and a mildly elevated amylase level. The hemodynamic status of the patients at the time of presentation ranges from normovolemia to profound hypovolemic shock with acidosis and is contingent upon the status of the bowel and the duration of symptoms.
A variety of diagnostic studies are available to help make the diagnosis of AMI secondary to an embolus. Plain abdominal radiographs have been used traditionally for patients with acute abdominal pain and can be helpful to demonstrate “free air” from an intestinal perforation or identify other causes of abdominal pain. However, patients with AMI frequently have either normal plain radiographs or demonstrate nonspecific findings (e.g., ileus). CT arteriography with 1- to 2-mm cuts has emerged as the diagnostic study of choice for patients with AMI secondary to an embolus (68–70). Notably, the study is performed using only intravenous contrast since both oral and rectal contrasts potentially interfere with the arteriogram itself. Both stenoses and occlusions in the visceral vessels are well demonstrated on CT arteriography. In patients with AMI secondary to an embolus, a “meniscus sign” can often be seen in the mid/distal superior mesenteric artery. The images obtained using the CT arteriogram protocol are also excellent for the nonvascular structures. The significant nonvascular findings of AMI include bowel wall thickening, bowel wall gas, bowel/solid organ infarction, and hepatic/portal venous gas. Notably, Paran et al. (69) reported that the majority of patients with portal/mesenteric venous gas had mesenteric ischemia and that the associated mortality rate was 86%. Mesenteric duplex, although an excellent screening test for CMI, is not usually helpful in patients with AMI because abdominal distention/gas precludes the accurate interrogation of the visceral vessels.
Standard catheter-based contrast arteriography can be used as an alternative to CT arteriography, and, indeed, has been the traditional imaging study for the visceral vessels in the setting of AMI from an embolus or in situ thrombosis. Similar to patients with CMI, it can potentially serve as both a diagnostic test and therapeutic modality since an intervention can be performed at the same time. The major disadvantages are the obligatory time required to obtain the procedure and the small, but finite, complications associated with the contrast agent and vessel cannulation. Given the new treatment algorithms with vascular surgeons assuming the traditional roles of the interventional radiologists, it is conceivable that the diagnostic catheter-based contrast arteriogram could be performed in an operating room with a fixed imaging unit. The definitive operative procedure could be performed at the same setting if the arteriogram confirmed the diagnosis.
Laparoscopy offers an additional diagnostic modality for patients with AMI (71,72). It can be used to assess the viability of the bowel and confirm the diagnosis. Furthermore, it can be performed in the intensive care unit with sedation and, therefore, is feasible for unstable patients with a suspected intra-abdominal process. Notably, the authors of the evidence-based guidelines from the European Association for Endoscopic Surgery concluded that laparoscopy had an unclear or limited role in the setting of AMI (73). However, they did state that it may be indicated if the routine diagnostic studies are inconclusive. Laparotomy remains the definitive diagnostic test for patients with AMI. However, the diagnostic studies outlined above are usually sufficient.
Treatment Strategies
Patients should be taken emergently to the operating room for definitive treatment once the diagnosis of AMI from an embolus is made. An extensive preoperative evaluation is unnecessary and potentially harmful in light of the narrow window for salvaging the bowel. There is essentially no role for medical management alone in this setting. Patients should be systemically anticoagulated with heparin to prevent further clot development and started on broad-spectrum antibiotics against enteric organisms. Importantly, patients with AMI are frequently hypovolemic and should be volume resuscitated prior to the induction of anesthesia. This can be performed fairly expeditiously and should not delay transfer to the operating room.
Both midline and transverse abdominal incisions provide adequate exposure to the visceral vessels and the choice is contingent upon surgeon preference. The diagnosis of AMI from an embolus is usually confirmed by the distribution of the ischemic/infarcted bowel that extends from the mid-jejunum to the transverse colon. However, the diagnosis should be further substantiated by interrogating the visceral vessels with continuous wave Doppler. The embolus may be extracted from the superior mesenteric artery using a Fogarty thromboembolectomy catheter. Although there are several approaches to the superior mesenteric artery, the easiest approach is to incise the base of the transverse mesocolon after retracting the transverse colon cephalad. The arteriotomy in the superior mesenteric artery may be performed either longitudinally or horizontally. Although the longitudinal arteriotomy needs to be closed with a vein patch to prevent narrowing its lumen, it is the preferred approach because it affords greater flexibility in case a bypass procedure is necessary.
The management of the bowel for patients with AMI merits further comment. All of the bowel that is obviously dead should be resected and intestinal anastomoses should be avoided in favor of proximal and distal stomas. This mandates a second procedure to restore bowel continuity, but it allows the bowel (i.e., mucosa of the stoma) to be examined at the bedside during the postoperative period. Furthermore, it avoids using ischemic or borderline ischemic tissues for the anastomosis. Bowel that is ischemic though not frankly necrotic should be revascularized and then re-examined before any final decision about resection. A conservative approach is justified in this setting because many of the borderline areas will remain viable after revascularization. Admittedly, the differentiation between viable and nonviable bowel is difficult. A variety of complicated modalities have been described to help differentiate viable from nonviable bowel in this setting although they have not been universally adopted. Simple adjuncts include visual inspection for peristalsis, use of continuous wave Doppler to detect arterial signals within the mesentery, and intravenous fluorescein in combination with a Wood lamp. Notably, approximately 100 to 150 cm of small bowel is necessary for nutritional absorption.
A decision to perform a second-look operation to reassess the viability of the bowel should be made at the time of the initial procedure. This is routinely performed 24 to 48 hours after the first procedure, a time usually sufficient for the marginal bowel to declare itself. A recent retrospective review has questioned the role of the second look operation and reported that survival was actually greater in those patients in which it was not performed (74). Admittedly, there was a tremendous selection bias in this review and the authors conceded that the experience of the surgeon is likely the key factor regarding the decision to perform a second look. A “damage control” operation may be justified in small subset of unstable patients with AMI as suggested by Freeman et al. (75). This includes emergent laparotomy, resection of obviously dead bowel, creation of proximal/distal stomas, leaving the abdomen open and deferring the definitive vascular/gastrointestinal procedure until later.
Despite its definitive role for patients with CMI, there is likely little role for endovascular therapies in patients with AMI secondary to an embolus. The obligatory time for endovascular treatment, including chemical lysis, is too long given the threatened bowel and the potential to progress from ischemic bowel to infarcted bowel. Furthermore, it does not allow direct assessment of the bowel and the chemical lysis may cause intestinal bleeding from mucosal sloughing. A systematic review of the literature examining the role of thrombolysis for acute superior mesenteric artery occlusion found insufficient evidence to support the practice despite a few case reports (76–82).
The postoperative course after embolectomy for AMI is similar to that after revascularization for CMI although the incidence of postoperative complications and multiple organ dysfunction are greater. As noted above, revascularization may cause an ischemia/reperfusion injury that affects both local and distant organ systems. Accordingly, patients are at risk for developing an abdominal compartment syndrome. Bladder pressures can be measured and the abdomen closure can be dissembled as necessary. Patients should be continued on broad-spectrum antibiotics throughout the early postoperative period. Furthermore, they need to be anticoagulated long term due to the potential for recurrent emboli.
Outcome
The mortality rate for patients with AMI is approximately 70% and this rate has changed very little over the past several decades (63,80,83,84). Unfortunately, the majority of the case series tend to encompass all of the etiologies rather than a specific one (e.g., embolus). A systematic review by Schoots et al. (80) reported that the mortality rates AMI from mesenteric venous thrombosis were better than those for arterial problems and that the mortality rates for mesenteric emboli were better than those for in situ thromboses. The aggregate mortality rates in their study by etiology are listed: mesenteric venous thrombosis, 32%; embolus, 54%; NOMI, 74%; in situ thrombosis, 77%. A variety of predictable factors have been associated with mortality in the various case series including patient age, time to definitive surgery, shock, acidosis, leukocytosis, cardiac status, and coagulopathy (83,85,86). Most deaths in a recent report were due to MOD (87).
In Situ Thrombosis
Patients with visceral artery occlusive disease may also present with AMI secondary to in situ thrombosis. The presentation is superimposed upon the symptoms of CMI in more than 50% of the patients (88) and can usually be differentiated from the other causes of AMI by the history and clinical setting. However, it is important to emphasize that patients may present with AMI as the initial symptom of their visceral occlusive disease. The clinical presentation, diagnostic approach, and immediate postoperative care of patients with the AMI secondary to in situ thrombosis is similar to that outlined above for emboli although the operative approach is somewhat different.
Patients with AMI secondary to in situ thrombosis require a mesenteric bypass. Although antegrade aortoceliac/superior mesenteric artery bypass is probably the optimal bypass for CMI, retrograde bypass from the infrarenal aorta, or common iliac artery is likely the optimal procedure for AMI (see Fig. 131.5). The objectives and treatment are somewhat different in the acute setting (i.e., AMI vs. CMI). The main objective is to restore blood flow to the ischemic vascular bed as safely and expeditiously as possible. This usually requires only bypass to the superior mesenteric artery. Patients with isolated celiac axis stenosis rarely develop AMI because the collateral blood flow to the foregut is so good and the liver may be sustained on portal blood flow alone. Prosthetic conduits are relatively contraindicated in the setting of bowel infarction and/or perforation due to the potential for postoperative graft infection. Autogenous conduits with either saphenous or superficial femoral vein are suitable although the latter may be more durable.
The role of endovascular treatment for patients with AMI secondary to in situ thrombosis is likely limited for the reasons noted above for AMI secondary to an embolus. Wyers et al. (89) have reported a small case series using novel hybrid open/endovascular approach in which a stent is placed retrograde through the superior mesenteric artery at the time of laparotomy. This approach allows assessment of the bowel and is potentially less morbid than the more traditional open revascularization.
Occasionally patients will undergo bowel resection for infarction by a nonvascular surgeon and the diagnosis of mesenteric ischemia will be missed both preoperatively and intraoperatively. It is important to emphasize that infarction of the bowel is not a spontaneous event, but rather an end-stage complication of another disease process; it is imperative that the etiology of all bowel infarctions be established in an attempt to prevent recurrences. An appropriate imaging study (i.e., CT arteriogram, catheter-based contrast arteriogram) should be obtained in the early postoperative and the necessary treatment including anticoagulation and revascularization implemented in a timely fashion.
Nonocclusive Mesenteric Ischemia
Pathophysiology
NOMI represents an abnormal or paradoxical mesenteric vasoconstriction characterized by the loss of autoregulation. Shock or “circulatory stress” normally causes mesenteric vasoconstriction in an attempt to maintain cerebral and/or cardiac perfusion. The mesenteric vasoconstriction ordinarily resolves when the underlying circulatory disorder is corrected; persistent vasoconstriction results in NOMI. There are multiple potential etiologies for NOMI including cardiogenic shock, sepsis, burn injury, trauma, pancreatitis, digitals, vasopressors, and renal failure (90–95). Indeed, almost any underlying condition that can precipitate shock or “circulatory stress” may precipitate NOMI.
Clinical Presentation and Diagnosis
Similar to the other causes of AMI, the diagnosis of NOMI requires a high index of suspicion and the proper clinical setting. Patients may develop abdominal pain although the physical examination is frequently unreliable due to the other active medical issues and altered sensorium. Laboratory abnormalities are common including acidosis, leukocytosis, elevated lactate levels, and hyperamylasemia, but these are all relatively nonspecific markers of the underlying shock state. Catheter-based contrast arteriography has traditionally been the diagnostic study of choice and is also potentially therapeutic. The significant findings on arteriogram for patients with NOMI include segmental stenosis/narrowing of the superior mesenteric artery in a “string of beads” appearance. Furthermore, there is narrowing of the branches of the superior mesenteric artery at their origins, spasm of the mesenteric arcades and impaired filling of the intramural branches. The arteriogram can also be helpful to rule out the other potential causes of AMI. The published experience with CT arteriography in the setting of NOMI is limited although it likely affords the same advantages as catheter-based contrast arteriography with fewer risks.
Treatment Strategies
The initial treatment of patients with NOMI is nonoperative and directed at correcting the underlying condition that precipitated the “circulatory stress.” Specifically, patients should be resuscitated in an attempt to improve their cardiac output and systemic perfusion. All vasoactive drugs should be stopped (if possible) and patients should be started on broad-spectrum antibiotics directed against enteric organisms. Furthermore, patients should be systemically anticoagulated unless contraindicated. Despite these efforts, the characteristic mesenteric vasoconstriction may persist. Continuous intra-arterial papaverine, administered through an infusion catheter placed into the superior mesenteric artery, may reverse the vasoconstriction (96,97). A 45-mg test dose of papaverine (i.e., short-acting calcium channel blocker) should be given over 15 minutes and a continuous infusion of 30 to 60 mg/hr should be started if no adverse reactions are encountered. Serial mesenteric arteriograms should be performed to monitor the response to the papaverine with the first performed 1 hour after initiating therapy. The intra-arterial infusion may be continued up to 24 hours. It should be noted that the infusion will reverse the mesenteric vasoconstriction only if the underlying hemodynamic instability is corrected. Operative treatment of NOMI should be reserved only for the clinical scenario when bowel infarction is suspected.
Mesenteric Venous Thrombosis
Pathophysiology
Mesenteric venous thrombosis may also result in AMI and is considered in this section for completeness. However, the associated degree of bowel ischemia is usually less than with arterial occlusion from either an embolus or in situ thrombosis. The pathophysiology is similar to venous thrombosis in other vascular beds and may be explained in terms of Virchow’s classic triad of stasis, intimal injury, and hypercoagulable states. Mesenteric venous thrombosis results in edema in the bowel and mesentery with significant third-space fluid losses. This may result in bloody ascites and, indeed, a bloody tap at the time of paracentesis may be diagnostic. Progression to bowel infarction is contingent upon the magnitude of the clot load and its distribution. Clot localized to the portal or superior mesenteric vein does not usually lead to bowel infarction because of the collateral channels whereas clot in the peripheral mesenteric veins is more likely to do so. The natural history of untreated mesenteric venous thrombosis is poor and almost universally progresses from bowel infarction to perforation and death.
Mesenteric venous thrombosis may result from abnormalities in any of the components of Virchow triad (i.e., stasis, intimal injury, hypercoagulable state). Stasis may result from congestive heart failure or portal hypertension while intimal injury may result from general anesthesia or any number of intra-abdominal infectious processes. A hypercoagulable state is perhaps the strongest of the contributory factors and has been identified in up to 90% of patients with mesenteric venous thrombosis (98).
Clinical Presentation and Diagnosis
Patients with mesenteric venous thrombosis usually present with vague, mild abdominal pain. The pain is usually insidious in onset and frequently present for some time before the patients seek medical attention. Furthermore, the pain is not usually localized to any specific quadrant. Physical examination is notable only for mild, diffuse abdominal pain. Peritoneal signs suggest bowel infarction, but are only found later in the disease process. An abdominal CT scan is the diagnostic study of choice (99,100). The significant findings include bowel edema and thrombus within the mesenteric veins with inflammation of the vessel wall (Fig. 131.6). Plain abdominal radiographs may suggest abdominal wall edema and are helpful to rule out other causes of the abdominal pain. Standard catheter-based contrast arteriography may be helpful, but is inferior to CT. The arteriographic findings that suggest mesenteric venous thrombosis include arterial spasm with a prolonged arterial phase, opacification of the bowel wall, extravasations of the contrast into the bowel lumen, and visualization of the venous thrombus.
FIGURE 131.6 CT scan from a patient with mesenteric venous thrombosis. Note the thrombus in the superior mesenteric vein at its confluence with the splenic vein as shown with the arrow.
Related posts:
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
